Cambridge, UK … Cambridge Combinatorial Ltd, a wholly owned subsidiary of Oxford Molecular Group plc (London Stock Exchange: OMG) today announced a series of collaborations with Pfizer at both the Groton site in the US and their Sandwich site in the UK. Through this collaboration, the two Pfizer sites will gain access to Cambridge Combinatorial’s novel automated process R&D, drug discovery platforms and chemistry technologies to augment their own in-house capabilities.

"Working with a company of Pfizer’s standing is obviously a great achievement for us," said Dr Allan Marchington, Chief Executive of Cambridge Combinatorial. "We are particularly excited about the range of projects we will be working on and the opportunity this collaboration offers to develop an ongoing relationship with a company as successful as Pfizer."

Cambridge Combinatorial Limited

Cambridge Combinatorial Limited provides world-class, innovative chemistry services to accelerate discovery and process research, servicing the pharmaceutical, agrochemical and biotechnology industries. The Company is a wholly owned subsidiary of Oxford Molecular Group Plc. Cambridge Combinatorial has developed leading technologies for discovery research including innovative molecular design, novel chemistries, new synthetic chemistry platforms and a comprehensive integrated informatics system. The company acts as an extension to the resources of its collaborators with solutions for discovery research including medicinal and combinatorial chemistry for lead generation, validation, optimisation and technology transfer as required.

Cambridge Combinatorial supplies the molecular design and synthesis arm of Oxford Molecular’s Collaborative Discovery. Collaborative Discovery acts as a central point for multi-disciplinary research projects involving both chemistry and biology research. Cambridge Combinatorial has secured many discovery collaborations with a range of pharmaceutical, agrochemical and biotechnology companies, spanning the US, Japan and Europe, these include: Procter & Gamble, Rohm & Haas, Solvay Duphar, Dainippon Pharmaceutical, Mitsubishi Chemical Corporation, Alizyme and Oxford Glycosciences.

Oxford Molecular Group plc

Oxford Molecular is a leading provider of discovery and software solutions to the life sciences market. The Company seeks to deliver excellence in all its products and services and to help its customers benefit from the synergy that is created from the integration of state-of-the-art chemistry, biology and information technology infrastructure.

The Discovery Solutions Division offers discovery research through collaboration, by providing world-class innovative technologies in chemistry and biology which intimately match customer needs and add value to their research programmes. The Software Solutions Division supplies enterprise-wide software and information technology solutions for research across the entire drug discovery process. Innovative and superior products target customer needs for excellence in each area of discovery research; and together they form integrated solutions that add value to the flow of information through the customer’s research process.